The assessment of flavin-containing monooxygenase activity in intact animals

Drug Metabolism and Drug Interactions

Volumn 13, Issue 1, 1996, Pages 1-28

  Damani, L A ^a   Nnane, I P ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CODEINE; CYTOCHROME P450; DEBRISOQUINE; DIAZEPAM; ETHYL METHYL SULFIDE; ISONIAZID; MEPHENYTOIN; PARACETAMOL; PHENACETIN; PHENAZONE; QUERCETIN; SPARTEINE; THEOPHYLLINE; TRIMETHYLAMINE; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE; WARFARIN;

ANIMAL EXPERIMENT; CONFERENCE PAPER; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; RAT;

EID: 0029920243     PISSN: 03342190     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.1996.13.1.1     Document Type: Conference Paper

References (110)

1. Ziegler DM, Jollow D, Cook D Properties of a purified microsomal mixed-function amine oxidase In: Kamin H, ed Flavins and Flavoproteins. Baltimore, MD: University Park Press, 1971; 504-522
2. Ziegler DM. Microsomal flavin-containing monooxygenases: oxygenation of nucleophilic nitrogen and sulphur compounds. In: Jakoby WB, ed. Enzymatic Basis of Detoxification, Vol. 1. New York: Academic Press, 1980; 201-227.
3. Liener JE. Toxic constituents of plant foodstuffs. 2nd Ed. New York: Academic Press, 1980.
4. Ziegler DM. Flavin-containing monooxygenase. Catalytic mechanism and substrate specificity. Drug Metab Rev 1988; 19: 1-32.
5. Ziegler DM Flavin-containing monooxygenases: enzymes adapted for multisubstrate specificity. TIPS 1990; 11: 321-324.
6. Ziegler DM Mechanism, multiple forms and substrate specificities of flavin-containing monooxygenase. In. Hlavica P, Damani LA, eds. N-Oxidation of Drugs. London: Chapman & Hall, 1991; 59-69.
7. Damani LA. Flavin-containing monooxygenase as an amine oxidase. In: Gorrod, JW, Oelschläger H, Caldwell J, eds. Metabolism of Xenobiotics. London: Taylor and Francis, 1988; 59-70.
8. Tynes RE, Sabourin PJ, Hodgson E. Identification of distinct hepatic and pulmonary forms of microsomal flavin-containing monooxygenase in the mouse and rabbit. Biochem Biophys Res Comm 1985; 126: 1069-1075.
9. 2-terminal segments homologous to the flavin-containing NADPH-monooxygenase of Pseudomonas fluorescens. Biochem Biophys Res Comm 1989; 163: 49-55.
10. Atta-Asfo-Adjei E, Lawton MP, Philpot RM. Cloning, sequencing, distribution and expression in Escherichia coli of flavin-containing monooxygenases 1C1. Evidence of a third gene subfamily in rabbits. J Biol Chem 1993, 268: 9681-9689.
11. Lawton, MP, Gasser R, Tynes RE, et al. The flavin-containing monooxygenase enzymes expressed in rabbit liver and lung are products of related but distinctly different genes J Biol Chem 1990; 265: 5855-5861.
12. Lawton MP, Cashman JR, Cresteil T, et al. The nomenclature for the mammalian flavin-containing monooxygenase gene family based on amino acid sequence identities. Arch Biochem Biophys 1994; 308: 254-257.
13. Conney AH, Pantuck EJ, Kuntzman R, et al Nutrition and chemical biotransformation in man Clin Pharmacol Ther 1977; 22: 707-722.
14. Remmer H, Merker H. Drug induced changes in liver endoplasmic reticulum: Association with drug metabolizing enzymes. Science, 1963, 142 1657-1660.
15. Gonzalez FJ. Molecular genetics of the P-450 superfamily. Pharmac Ther 1990, 45. 1-38.
16. Testa B Mechanisms of inhibition of xenobiotic-metabolizing enzymes. Xenobiotica 1990, 20: 1129-1137
17. Masters BSS, Ziegler DM. The distinct nature and function of NADPH-dependent mixed function amide oxidase by N-1(1-methylcyclopropyl)-benzylamine Biochemistry 1984, 23: 1322-1338
18. Silverman RB, Yamasaki RB. Mechanism-based inactivation of mitochondrial monoamine oxidase by N-(1-methylcyclopropyl)benzylamine Biochemistry 1984, 23: 1322-1338.
19. Kaderlik RK, Weser E, Ziegler DM Selective loss of liver flavin-containing monooxygenase in rats on chemically defined diets. Prog Pharmacol Clin Pharmacol 1991; 8: 95-103.
20. Nnane IP, Damani LA. Ethyl methyl sulphide A potential probe for monitoring the activity of the flavin-containing monooxygenase in vivo. Br J Clin Pharmacol 1992, 34: 160-161.
21. Krieter PA, Ziegler DM, Hill KA, et al. Increased biliary GSSG efflux from rat livers perfused with thiobenzamide substrates for the flavin-containing monooxygenase Mol Pharmacol 1984; 26: 122-127.
22. Das ML, Zieger DM. Rat liver oxidative N-oxidative, N-dealkylase and N-oxidase activities as a function of animal age. Arch Biochem Biophys 1970; 140: 300-306
23. Dixit A, Roche TE. Spectrophotometric assay of the flavin-containing monooxygenase. Changes in its activity in female mouse liver with nutritional and diurnal conditions. Arch Biochem Biophys 1984; 233: 50-63.
24. Ross LH, Jurkovitch G, Rauckman E, Grant J. Hepatotoxic effects of parenteral nutrition: an investigation of rat microsomal enzymes. J Paren Ent Nutr 1982; 6: 579.
25. Damani LA. Reduction and conjugation reactions of N-oxides. In: Hlavica P, Damani LA, eds N-Oxidation of Drugs. London: Chapman and Hall, 1991: 239-261.
26. Nnane IP, Damani LA. Pharmacokinetics of trimethylamine: Approach for monitoring the activity of the flavin-containing monooxygenase in vivo. J Pharm Pharmacol 1992; 44. 1060.
27. Nnane IP. Metabolic and pharmacokinetic studies on model sulphides. Ph.D. Thesis, University of London, 1992, 258-310.
28. Boobis AR, Davies DS Human cytochrome P-450 Xenobiotica 1984; 14: 151-185.
29. Park BK. Assessment of drug metabolism capacity of the liver. Br J Clin Pharmacol 1982; 14: 631-651
30. Damani LA Oxidation at nitrogen centres. In: Jakoby WB, Bend JR, Caldwell J, eds. Metabolic Basis of Detoxication. New York, London: Academic Press, 1982; 127-149.
31. Hoodi AA, Damani LA. Sulphoxidation of tetrahydrothiophene and its acyclic analogue, diethylsulphide. In: Mitchell SC, Waring RH, eds. Sulphur in Xenobiotics. Birmingham, UK. Birmingham University Press, 1983; 131-138.
32. Damani LA, ed. Sulphur-Containing Drugs and Related Organic Compounds. Chichester: Ellis Horwood Ltd, 1989; Vols. 1-3.
33. Schenkman JB, Remmer H, Estabrook RW. Spectral studies of drug interactions with hepatic microsomal cytochrome P-450. Mol Pharmacol 1967; 3: 113-123.
34. Poland AP, Nebert DW A sensitive radiometric assay for aminopyrine N-demethylation. J Pharmacol Exp Ther 1973; 184: 269-277.
35. Minck K, Schupp RR, Illing HP, et al. Interrelationship between demethylation of p-nitroanisole and conjugation of p-nitrophenol in rat liver. Naunyn Schmiedebergs Arch Pharmacol 1973; 279: 347-360.
36. Greenlee WF, Poland A. An improved assay of 7-ethoxycoumarin O-deethylase activity: induction of hepatic enzyme activity in C57BL/6J and DBA/2J mice by phenobarbital,3-methylcholanthrene and 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Pharmacol Exp Ther 1978; 205: 596-605
37. Nebert DW, Gelboin HV The in vivo and in vitro induction of aryl hydrocarbon hydroxylase in mammalian cells of different species, tissues, strains, and developmental and hormonal states. Arch Biochem Biophys 1969; 134: 76-89.
38. Lake BG. Preparation and characterisation of microsomal fractions for studies on xenobiotic metabolism. In: Snell K, Mullock B, eds. Biochemical Toxicology. A Practical Approach. Oxford: IRL Press, 1987; 182-215.
39. Burke MD, Mayer RT. Inherent specificities of purified cytochromes P-450 and P-448 towards biphenyl hydroxylation and ethoxyresorufin deethylation. Drug Metab Dispos 1975; 3: 245-250.
40. Guengerich FP. Reactions and significance of cytochrome P450 enzymes. J Biol Chem 1991; 266: 10019-10022.
41. Murray M. P-450 enzymes: Inhibition mechanisms, genetic regulation and effects of liver disease. Clin Pharmacokinet 1992; 23: 132-146.
42. Nelson DR, Kamataki T, Waxman DJ, et al. The P-450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes and nomenclature. DNA Cell Biol 1993; 12. 1-51.
43. Gonzalez FJ, Nebert DW. Evolution of the P-450 gene superfamily. Trends in Genetics 1990, 6 182-186.
44. Gibson GG, Skett P Introduction to Drug Metabolism, 2nd Ed London: Blackie Academic and Professional, 1994; 191-199.
45. Danhof M, Van Zuilen A, Boeijinga JK, et al. Studies of the different metabolic pathways of antipyrine in man. Eur J Clin Pharmacol 1982; 21: 433-441.
46. Vessell ES. The antipyrine test in clinical pharmacology Conceptions and misconceptions. Clin Pharmacol Ther 1979; 26: 275-286
47. Dossing M, Poulsen HE, Andreasen PB, et al. A simple method for determination of antipyrine clearance Clin Pharmacol Ther 1982; 32: 392-396.
48. Kawasaki S, Imamura H, Kokudo N, et al. A comparison between antipyrine and aminopyrine blood clearances. Hepato-Gastroenterol 1992; 39: 344-346
49. Fabre D, Bressolle F, Goméni R, et al. Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters. Clin Pharmacokinet 1993; 24: 333-343.
50. Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF Human cytochrome P450PA(P4501 A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and V-oxidation of carcinogenic arylamines PNAS 1989, 86: 7696-7700.
51. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/ sparteine metabolism - clinical aspects Pharmacol Ther 1990, 46 377-394.
52. Wilkinson GR, Shand DG A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975, 18. 377-390
53. Brockmöller J, Roots I Assessment of liver metabolic function. Clinical implications. Clin Pharmacokinet 1994; 27 216-248
54. Kalow W, Tang BK. Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 1994, 49-44-48
55. Anderson PB, Hendel J, Greisen G, et al Pharmacokinetics of diazepam in adult man. J Clin Invest 1975; 10. 115-120
56. Boobis AR, Fawthrop DJ, Seddon CE, et al. Variability in the pharmacokinetics and metabolism of acetominophen. In: Karlow W, ed Pharmacognetics of Drug Metabolism. New York Pergamon Press, 1992; 791-812
57. Staib AH, Schuppan D, Lissner R, et al. Pharmacokinetics and metabolism of theophylline in patients with liver disease. J Clin Pharmacol Ther Toxicol 1980; 18: 500-502
58. Jacobi A, Levy G Comparative pharmacokinetics of coumarin anticoagulants. XIV Relationship between protein binding, distribution, and elimination kinetics of warfarin in rats J Pharm Sci 1975; 64: 1660-1664.
59. Ladona MJ, Lindstrom B, Thyr C, et al. Differential foetal development of the O- and N-demethylation of codeine and dextromethorphan in man. Br J Clin Pharmacol 1991; 32: 295-302.
60. Hutchings A, Routledge PA. A simple method for determining acetylator phenotype using isoniazid. Br J Clin Pharmacol 1986; 22: 343-345
61. Clement B, Lustig KL, Ziegler DM Metabolism of promethazine catalysed by porcine liver flavin-containing monooxygenase. Prog Pharmacol Clin Pharmacol 1991, 8 127-136.
62. Ohmiya Y, Mehendale HM Species differences in pulmonary V-oxidation of chlorpromazine and imipramine. Fed Proc 1981; 40: 732.
63. Lemoine A, Johann M, Cresteil T. Evidence for the presence of distinct flavin-containing monooxygenases in human tissues. Prog Pharmacol Clin Pharmacol 1991; 8: 105-115.
64. Gold MS, Ziegler DM Dimethylaniline N-oxidase and aminopyrine N-demethylase activities of human liver tissue. Xenobiotica 1973; 3 179-189.
65. Sherratt AJ, Damani LA Activities of cytosolic and microsomal drug oxidases of rat hepatocytes in primary culture Drug Metab Dispos 1989, 17: 20-25.
66. Hlavica P, Kehl M. Studies on the mechanism of hepatic microsomal N-oxide formation The role of cytochrome P-450 and mixed function amine oxidase in the N-oxidation of N,N-dimethylaniline Biochem J 1977; 164 187-196.
67. Cashman JR, Hanzlik PP Microsomal oxidation of thiobenzamide. A photometric assay for the flavin-containing monooxygenase Biochem Biophys Res Comm 1981; 98 147-153
68. Levi PA, Tynes RE, Sabourin PJ, Hodgson E. Is thiobenzamide a specific substrate for the microsomal FAD-containing monooxygenase? Biochem Biophys Res Comm 1982; 107. 1314-1318.
69. Hoodi AA. Studies on metabolic sulphoxidation of alkyl and aryl thioethers: Role of cytochrome P-450 and FAD-containing monooxygenase. Ph.D. Thesis, University of Manchester, 1986, 276-311
70. Hoodi AA, Damani LA Cytochrome P-450 and non-cytochrome P-450 sulphoxidations. J Pharm Pharmacol 1984, 36(suppl): 629.
71. Williams DE, Reed RL, Kedzierski B, et al. The role of flavin-containing monooxygenase in the N-oxidation of the pyrrolizidine alkaloid senecionine. Drug Metab Dispos 1989; 17: 380-386.
72. Nnane IP, Damani LA. Effects of synthetic amino acid diet on the in vitro sulphoxidation of ethyl methyl sulphide. Unpublished data.
73. Mani C, Hodgson E, Kupfer D. Metabolism of the antimammary cancer antiestrogenic agent, Tamoxifen. 11. Flavin-containing monooxygenase-mediated N-oxidation Drug Metab Dispos 1993, 21 657-661.
74. Damani LA, Pool WF, Crooks PA, et al. Stereoselectivity in the N-oxidation of nicotine isomers by flavin-containing monooxygenase. Mol Pharmacol 1988; 33: 702-705
75. Hadley MR, Svajdlenka E, Damani LA, et al. Species variability in the stereoselective N-oxidation of pargyline. Chirality 1994; 6: 91-97.
76. Hadley MR, Oldham HG, Damani LA, Hutt AJ. Assymmetric metabolic N-oxidation of N-ethyl-N-methylaniline by purified flavin-containing monooxygenase Chirality 1994; 6: 98-104.
77. Kuzel RA, Bhasin SK, Oldham GH, et al. Investigations into the metabolic sulfoxidation of cimetidine. Chirality 1994; 6: 607-614
78. Cashman JR, Park SB, Berkman CE, Cashman LE. Role of hepatic flavin-containing monooxygenase 3 in drug and chemical metabolism in adult humans. Chem Biol Interact 1995; 96: 33-46
79. Damani LA. Colorimetric and chromatographic assay of tertiary amine N-oxides. In: Gorrod JW, Damani LA, eds. Biological Oxidation of Nitrogen in Organic Molecules. Chichester: Ellis Horwood Ltd, 1985; 33-39.
80. Kadlubar FF, Mckee EM, Ziegler DM. Reduced pyridine nucleotide dependent A-hydroxyamine oxidase and reductase activities of hepatic microsomes. Arch Biochem Biophys 1973; 156: 46-57.
81. Mitchell CH, Ziegler DM. A quantitative micro method for the estimation of amine oxides. Anal Biochem 1969; 28: 261-268.
82. Rettie AE, Lawton MP, Sadeque AJ, et al Prochiral sulfoxidation as a probe for multiple forms for the microsomal flavin-containing monooxygenase: studies with rabbit FMO1, FMO2, FMO3 and FMO5 expressed in Escherichia coli Arch Biochem Biophys 1994; 311: 369-377.
83. Rettie AE, Meier GP, Sadeque AJ. Prochiral sulfoxides as in vitro probes for multiple forms of the flavin-containing monooxygenase. Chem Biol Interact 1995; 96: 3-15.
84. Hadley MR, Oldham HG. Camilleri P, et al. Stereoselective microsomal N-oxidation of N-ethyl-N-methylaniline. Biochem. Pharmacol 1993, 45. 1739-1742.
85. Hadley MR, Damani LA, Hutt AJ, et al. Enantiomeric resolution of N-alkyl-N-methylaniline N-oxides by high-performance liquid chromatography. Chromatographia 1993, 37: 487-491.
86. Gut I, Conney AH. Trimethylamme N-oxygenation and N-demethylation in rat liver microsomes. Biochem Pharmacol 1993, 46 239-244.
87. Cashman JR, Celestial JR, Leach A, et al. Tertiary amines related to brompheniramine. preferred conformations for N-oxygenation by the hog liver flavin-containing monooxygenases Pharm Res 1993; 10: 1087-1105.
88. Kawaji A, Ohara K, Takabatake E. An assay of flavin-containing monooxygenase activity with benzydamine N-oxidation Anal Biochem 1993; 214: 409-412.
89. Kawaji A, Ohara K, Takabatake E Determination of flavin-containing monooxygenase activity in rat brain microsomes with benzydamaine N-oxidation. Biol Pharm Bull 1994, 17 663-666
90. Lee MY, Smiley S, Kadkhodayan S, et al. Developmental regulation of flavin-containing monooxygenase (FMO) isoforms 1 and 2 in pregnant rabbit. Chem Biol Interact 1995; 96: 75-85.
91. Poulsen LL, Ziegler DM. Multisubstrate flavin-containing monooxygenase: Applications of mechanisms to specificity. Chem Biol Interact 1995; 96: 57-73.
92. Poulsen LL, Taylor K, Williams DE, et al. Substrate specificity of the rabbit lung flavin-containing monooxygenase for amines: Oxidation products of primary alkylamines Mol Pharmacol 1986; 30: 680-685.
93. McManus ME, Grantham PH, Cone JL, et al Guanethidine N-oxide formation as a measure of cellular flavin-containing monooxygenase activity. Biochem Biophys Res Comm 1983; 112. 437-443
94. Nagata T, Williams DE, Ziegler DM. Substrate-specificity of rabbit lung and porcine liver flavin-containing monooxygenases. differences due to substrate size. Chem Res Toxicol 1990; 3: 372-376
95. Guo WX, Poulsen LL, Ziegler DM Use of thiocarbamides as selective substrate probes for isoforms of flavin-containing monooxygenases. Biochem Pharmacol 1992; 44. 2029-2037
96. Lomri N, Yang Z, Cashman JR. Regio- and stereoselective oxygenations by adult human liver flavin-containing monooxygenase 3 Comparison with forms 1 and 2. Chem Res Toxicol 1993; 6: 800-807.
97. Hines RN, Cashman JR, Philpot RM, et al. The mammalian flavin-containing monooxygenases. Molecular characterisation and regulation of expression Toxicol Appl Pharmacol 1994, 125 1-6.
98. Hoodi AA, Damani LA A-Demethylation and N-oxidation of N,N-dimethylaniline by rat liver microsomes. In. Gorrod JW, Damani LA, eds Biological Oxidation of Nitrogen in Organic Molecules. Chichester: Ellis Horwood Ltd, 1985; 96-100
99. Damani LA, Hoodi AA Cytochrome P-450 and FAD-monooxygenase mediated S- and N-oxygenations Drug Metab Drug Interact 1988, 6: 235-244.
100. Al-Waiz M, Ayesh R, Mitchell SC, et al. A genetic polymorphism of the N-oxidation of trimethylamine in humans. Clin Pharmacol Ther 1987; 44: 588-594.
101. Al-Waiz M, Ayesh R, Mitchell SC, et al. Trimethylaminuria ('Fish-odour Syndrome"): A study of an affected family. Clin Sci 1988; 74: 231-236.
102. Al-Waiz M, Ayesh R, Mitchell SC, et al. Trimethylaminuria: the detection of carriers using a trimethylamine load test. J Inherited Metab Dis 1989; 12: 80-85.
103. Cholerton S, Smith RL. Human pharmacogenetics of nitrogen oxidations. In: Hlavica P, Damani LA, eds. N-Oxidation of Drugs. London: Chapman and Hall, 1991; 107-131.
104. Cholerton S, Ayesh R, Idle JR, Smith RL. The pre-eminence of nicotine N-oxidation and its diminution after carbimazole administration. Br J Clin Pharmacol 1988; 26: P652.
105. Ayesh R, Al-Waiz M, Crothers MJ, et al. Deficient nicotine N-oxidation in two sisters with trimethylaminuria. Br J Clin Pharmacol 1988; 25: 664.
106. Lanusse CE, Prichard RK. Effects of methimazole on the kinetics of netobimin metabolites in cattle. Xenobiotica 1992; 22: 115-123.
107. Rouer E, Rouet P, Delpech M, Lerous JP. Purification and comparison of liver microsomal flavin-containing monooxygenase from normal and streptozotocin-diabetic rats. Biochem Pharmacol 1988; 37: 3455-3459.
108. Lee MV, Clark JE, Williams DE. Induction of flavin-containing monooxygenase (FMO B) in rabbit lung and kidney by sex steroids and glucocorticoids. Arch Biochem Biophys 1993; 302: 332-336.
109. Brodfuehrer JI, Zannoni VG. Flavin-containing monooxygenase and ascorbic acid deficiency. Qualitative and quantitative differences. Biochem Pharmacol 1987; 36: 3161-3167.
110. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994; 4: 171-184.